Impact of cyclooxygenase-2 in breast cancer

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4359-4367

  Hoellen, Friederike ^a   Kelling, Katharina ^a   Dittmer, Christine ^a   Diedrich, Klaus ^a   Friedrich, Michael ^b   Thill, Marc ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

Breast cancer; Carcinogenesis; COX 2; Cyclooxygenase; Prostaglandin; Tumor

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; CALCITRIOL; CD31 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; IBUPROFEN; INDOMETACIN; LEUKOTRIENE; LIPOXYGENASE; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE; PHOSPHOLIPASE A1; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN F2 ALPHA; PROTEIN BAX; PROTEIN BCL 2; ROFECOXIB; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE SYNTHASE; VASCULOTROPIN C;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARACHIDONIC ACID METABOLISM; BREAST CANCER; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; ENZYME METABOLISM; ENZYME REPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; PROGNOSIS; PROSTAGLANDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855184409     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581-592, 2007. (Pubitemid 46359643)
2. Pakkiri P, Lakhani SR and Smart CE: Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology 41(1): 89-99, 2009.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4): 320-368, 2009.
4. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D and Paepke S: uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 45: 31-45, 2008.
5. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93(4): 497-506, 2001. (Pubitemid 32701408)
6. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S and DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4): 1183-1188, 1994. (Pubitemid 24294584)
7. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR and Shen Y: Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117(2): 350-358, 1999. (Pubitemid 29352943)
8. Ristimaki A, Jaatinen R and Ritvos O: Regulation of prostaglandin F 2 alpha receptor expression in cultured human granulosa-luteal cells. Endocrinology 138(1): 191-195 1997. (Pubitemid 27009423)
9. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T and Haglund C: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3): 632-635, 2002. (Pubitemid 34126931)
10. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE and Schror K: Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59(1): 198-204, 1999. (Pubitemid 29062978)
11. Swami S, Krishnan AV, Moreno J, Bhattacharyya RB, Peehl DM and Feldman D: Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr 137(1 Suppl): 205S-210S, 2007. (Pubitemid 46052882)
12. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24(2): 96-102, 2003. (Pubitemid 36135884)
13. Heinonen PK and Metsa-Ketela T: Prostaglandin and thromboxane production in ovarian cancer tissue. Gynecol Obstet Invest 18(5): 225-229, 1984. (Pubitemid 15182084)
14. Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V and Malone JM Jr.: Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192(3): 819-825, 2005. (Pubitemid 40311275)
15. Ranger GS, Thomas V, Jewell A and Mokbel K: Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 24(4): 2349-2351, 2004. (Pubitemid 39166317)
16. Coussens LM and Werb Z: Inflammation and cancer. Nature 420(6917): 860-867, 2002. (Pubitemid 36019639)
17. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299(1): 125-140, 1996.
18. Murakami M and Kudo I: Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 43(1): 3-35, 2004. (Pubitemid 37433865)
19. Stack E and DuBois RN: Regulation of cyclo-oxygenase-2. Best Pract Res Clin Gastroenterol 15(5): 787-800, 2001. (Pubitemid 32982366)
20. Williams CS, DuBois RN: Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 270(3 Pt 1): G393-400, 1996.
21. Abdel-Latif ME, Bolisetty S, Abeywardana S and Lui K: Mode of delivery and neonatal survival of infants with gastroschisis in Australia and New Zealand. J Pediatr Surg 43(9): 1685-1690, 2008.
22. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI and Chulada PC: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83(3): 483-492, 1995.
23. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R and Trzaskos JM: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91(2): 197-208, 1997. (Pubitemid 27456387)
24. Davis BJ, Lennard DE, Lee CA, Tiano HF, Morham SG and Wetsel WC: Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E 2 and interleukin-1beta. Endocrinology 140(6): 2685-2695, 1999. (Pubitemid 32245148)
25. Loftin CD, Trivedi DB, Tiano HF, Clark JA, Lee CA, Epstein JA, Morham SG, Breyer MD, Nguyen M, Hawkins BM, Goulet JL, Smithies O, Koller BH and Langenbach R: Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci USA 98(3): 1059-1064, 2001. (Pubitemid 32121186)
26. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S and Kobel M: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 97(12): 2978-2987, 2003. (Pubitemid 36676251)
27. 2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol 121(1-2): 387-390, 2010.
28. Ristimaki A, Honkanen N, Jankala H, Sipponen P and Harkonen M: Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57(7): 1276-1280, 1997. (Pubitemid 27152551)
29. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2(11): 632-642, 2004. (Pubitemid 39557666)
30. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR and Pockaj BA: A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 8(6): R69, 2006.
31. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62(6): 1676-1681, 2002. (Pubitemid 34408488)
32. Singh-Ranger G, Salhab M and Mokbel K: The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109(2): 189-198, 2008.
33. Watanabe O, Shimizu T, Imamura H, Kinoshita J, Utada Y and Okabe T: Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 23(4): 3215-3221, 2003. (Pubitemid 36980582)
34. Yoshimura N, Sano H, Okamoto M, Akioka K, Ushigome H and Kadotani Y: Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today 33(11): 805-811, 2003. (Pubitemid 37357652)
35. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, Salehin D and Friedrich M: Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res 29(9): 3619-3625, 2009.
36. Thill M, Hoellen F, Kelling K, Dittmer C, Landt S, Salehin D, Diedrich K, Friedrich M and Becker S: Correlation of cyclooxygenase-2 and vitamin D receptor expression with 25(OH)-2D-3 serum levels in normal and malignant breast tissue. Anticancer Res 30(5): 1673-1679, 2010.
37. Zhao Y, Agarwal VR, Mendelson CR and Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137(12): 5739-5742, 1996. (Pubitemid 26423150)
38. Chen LY, Lawson DL and Mehta JL: Reduction in human neutrophil superoxide anion generation by n-3 polyunsaturated fatty acids: role of cyclooxygenase products and endothelium-derived relaxing factor. Thromb Res 76(4): 317-322, 1994. (Pubitemid 24343530)
39. Tanabe T and Tohnai N: Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69: 95-114, 2002. (Pubitemid 35247390)
40. Tanaka T, Haneda S, Imakawa K, Sakai S and Nagaoka K: A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 77(2): 181-187, 2009.
41. Jackson RJ SN: How do microRNAs regulate gene expression? Sci STKE. 367(re1), 2007.
42. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A and Chen J: Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120(5): 623-634, 2005. (Pubitemid 40343075)
43. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T and Hla T: Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 269(16): 11769-11775, 1994.
44. Evett GE, Xie W, Chipman JG, Robertson DL and Simmons DL: Prostaglandin G/H synthase isoenzyme 2 expression in fibroblasts: regulation by dexamethasone, mitogens, and oncogenes. Arch Biochem Biophys 306(1): 169-177, 1993. (Pubitemid 23291299)
45. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A and Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274(16): 10911-10915, 1999.
46. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT and Smith E: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276(21): 18563-18569, 2001.
47. Diaz-Cruz ES, Shapiro CL and Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90(5): 2563-2570, 2005. (Pubitemid 40686292)
48. Cuzick J, Otto F, Baron JA, Brown PH, Burn J and Greenwald P: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5): 501-507, 2009.
49. Zhao YS ZS, Li XW, Wang F, Hu FL, Li DD, Zhang WC and Li X: Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res 2009.
50. Khuder SA, Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9): 1188-1192, 2001. (Pubitemid 32511336)
51. Cotterchio M, Kreiger N, Sloan M and Steingart A: Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10(11): 1213-1217, 2001. (Pubitemid 33064311)
52. Karmali RA, Thaler HT and Cohen LA: Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea-induced rat mammary adenocarcinoma. Eur J Cancer Clin Oncol 19(6): 817-823, 1983. (Pubitemid 13058377)
53. Rolland PH, Martin PM, Jacquemier J, Rolland AM and Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64(5): 1061-1070, 1980. (Pubitemid 10100318)
54. Schrey MP and Patel KV: Prostaglandin E 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72(6): 1412-1419, 1995.
55. Kawamori T and Wakabayashi K: COX-2 and prostanoid receptors: good targets for chemoprevention. J Environ Pathol Toxicol Oncol 21(2): 149-153, 2002. (Pubitemid 34655035)
56. Tsuboi K, Sugimoto Y and Ichikawa A: Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 68-69: 535-556, 2002. (Pubitemid 35247419)
57. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A and Lin BT: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66(15): 7818-7823, 2006. (Pubitemid 44289243)
58. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B and Kwong E: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5): 803-809, 1996. (Pubitemid 26404280)
59. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA and Qualtrough D: Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66(6): 3106-3113, 2006.
60. Sugimoto Y and Narumiya S: Prostaglandin E receptors. J Biol Chem 282(16): 11613-11617, 2007. (Pubitemid 47100657)
61. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11): 1589-1594, 2000. (Pubitemid 30390309)
62. Davies G, Salter J, Hills M, Martin LA, Sacks N and Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9(7): 2651-2656, 2003. (Pubitemid 36842109)
63. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX and Wan L: Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 8: 4, 2008.
64. Nassar A, Radhakrishnan A, Cabrera IA, Cotsonis G and Cohen C: COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15(3): 255-259, 2007. (Pubitemid 47329915)
65. Holmes MD, Chen WY, Schnitt SJ, Collins L, Colditz GA and Hankinson SE: COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130(2): 657-662, 2011.
66. Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56(22): 5125-5127, 1996.
67. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG and Mokbel K: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol 96(5): 424-428, 2007. (Pubitemid 47519449)
68. Vienonen A, Syvala H, Miettinen S, Tuohimaa P and Ylikomi T: Expression of progesterone receptor isoforms A and B is differentially regulated by estrogen in different breast cancer cell lines. J Steroid Biochem Mol Biol 80(3): 307-313, 2002. (Pubitemid 34304153)
69. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M and Crotty TB: Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 15(3): 745-753, 2008.
70. Chen B, Su B and Chen S: A COX-2 inhibitor nimesulide analog selectively induces apoptosis in HER2 overexpressing breast cancer cells via cytochrome c-dependent mechanisms. Biochem Pharmacol 77(12): 1787-1794, 2009.
71. Kang JH, Song KH, Jeong KC, Kim S, Choi C and Lee CH: Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer 11(1): 334, 2011.
72. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F and Bennington J: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9): 627-637, 2010.
73. Glover JA, Hughes CM, Cantwell MM and Murray LJ: A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer 105(1): 13-7, 2011.
74. Lari SA and Kuerer HM: Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2: 232-261, 2011.
75. Perrone MG, Scilimati A, Simone L and Vitale P: Selective COX-1 inhibition: A therapeutic target to be reconsidered. Curr Med Chem 17(32): 3769-3805, 2010.
76. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90(6): 455-460, 1998. (Pubitemid 28160637)
77. Kirtikara K, Morham SG, Raghow R, Laulederkind SJ, Kanekura T and Goorha S: Compensatory prostaglandin E 2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 187(4): 517-523, 1998. (Pubitemid 28093354)
78. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF and Hanley JA: Nested case control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83(1): 112-120, 2000. (Pubitemid 30352727)
79. Harris RE, Namboodiri KK and Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7(2): 203-205, 1996. (Pubitemid 26068056)
80. Alshafie GA, Abou-Issa HM, Seibert K and Harris RE: Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 7(6): 1377-1381, 2000.
81. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60(8): 2101-2103, 2000. (Pubitemid 30225166)
82. Barnes NL, Warnberg F, Farnie G, White D, Jiang W and Anderson E: Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96(4): 575-582, 2007.
83. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N and Otsuki Y: COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res 26(6B): 4245-4254, 2006. (Pubitemid 46031497)
84. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM and Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65(17): 7917-7925, 2005. (Pubitemid 41297270)
85. Falandry C, Debled M, Bachelot T, Delozier T, Cretin J and Romestaing P: Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 116(3): 501-508, 2009.
86. Canney PA, Machin MA and Curto J: A feasibility study of the efficacy and tolerability of the combination of exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer 42(16): 2751-2756, 2006. (Pubitemid 44584673)
87. Chow LW, Yip AY, Loo WT, Lam CK and Toi M: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 111(1-2): 13-17, 2008.
88. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H and Raghunadharao D: Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 26(8): 1253-1259, 2008.
89. Fabi A, Metro G, Papaldo P, Mottolese M, Melucci E and Carlini P: Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 62(4): 717-725, 2008.
90. Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA and Yang P: Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila) 1(3): 208-214, 2008.
91. Li W, Zhang HH, Xu RJ, Zhuo GC, Hu YQ and Li J: Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo. Med Oncol 25(2): 172-177, 2008.
92. Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL and Dannenberg AJ: Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot Essent Fatty Acids 66(1): 13-8, 2002. (Pubitemid 34717684)
93. Denken C, Kobel M, Pest S, Koch I, Berger S and Schwabe M: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160(3): 893-903, 2002. (Pubitemid 34224579)
94. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I and Schmitt FC: Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55(6): 429-434, 2002. (Pubitemid 34620779)
95. Kelly LM, Hill AD, Kennedy S, Connolly EM, Ramanath R and Teh S: Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29(9): 707-710, 2003. (Pubitemid 37483941)
96. Lim SC: Role of COX-2, VEGF and cyclin D1 in mammary-infiltrating duct carcinoma. Oncol Rep 10(5): 1241-1249, 2003.
97. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C and Heinecke A: Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129(7): 375-382, 2003. (Pubitemid 36995136)
98. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90(2): 423-429. PMCID: 2409574, 2004.
99. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P and Ghilchik M: The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 18(4): 237-241, 2002.
100. Singh-Ranger G, Kirkpatrick KL, Clark GM and Mokbel K: Cyclo-oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 19(2): 131-134, 2003. (Pubitemid 36548128)
101. Zhao XQ, Pang D and Xue YW: Expression of the cyclooxygenase-2 gene in human breast carcinoma. Zhonghua Wai Ke Za Zhi 41(6): 427-429, 2003 (in Chinese).